A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

CompletedOBSERVATIONAL
Enrollment

207

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Hereditary Angioedema (HAE)
Trial Locations (20)

1090

Medizinische Universitat Wien (Medical University of Vienna), Vienna

4021

Kepler Universitätsklinikum Linz, Linz

8036

LKH-Universitätsklinikum Klinikum Graz, Graz

10117

Charitè Campus Mitte, Berlin

15125

University General Hospital of Larissa, Larissa

30625

Medizinische Hochschule Hannover, Hanover

34295

CHU Montpellier - Hôpital St Eloi, Montpellier

38043

CHU de Grenoble, Grenoble

48149

Universitatsklinikum Munster, Münster

59800

CHRU Lille, Lille

60596

Universitätsklinikum Frankfurt, Frankfurt am Main

64546

Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf

69437

Groupement Hospitalier Edouard Herriot, Lyon

75181

Hôtel Dieu de Paris Hospital, Paris

75571

Hôpital Saint Antoine, Paris

76031

Centre Hospitalier Universitaire Hopitaux de Rouen, Rouen

80802

Klinikum rechts der Isa der Technischen Universitaet Muenchen, Munich

89075

Universitätsklinikum Ulm, Ulm

115 21

Navy Hospital of Athens, Athens

115 27

Laiko General Hospital of Athens, Athens

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY